ABBV

$ABBV

AbbVie Inc.

Biopharmaceutical company known for Humira, Skyrizi, and Rinvoq immunology drugs.

Healthcare
$293.39
-1.16 (-0.39%)
Day Range$291.00 - $294.09
Prev Close$294.55

ABBV key facts as of November 14, 2026

Latest AI research report
ABBV Research: Growth, Valuation and Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Strong Buy (7 Strong Buy, 16 Buy, 5 Hold, 0 Sell, 1 Strong Sell) (as of November 1, 2026)
Analyst price target
$313.80 mean (range $275.00 to $340.00) (as of November 17, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
23 Buy / 5 Hold / 1 Sell
Price Target
$313.80
7.0% upside
Subscribers
1
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

NEUTRAL

ABBV Research: Growth, Valuation and Risks

AbbVie enters the weekend near its 52-week high after an adjusted earnings beat and strong growth from Skyrizi and Rinvoq. The company’s growth outlook and analyst support are balanced by a rich trailing P/E, modest consensus target upside, debt, and ongoing Humira erosion.

Nov 14, 2026

ABBV FAQ

What is StockAlpha's latest view on ABBV?

StockAlpha's latest AI research report on AbbVie Inc. (ABBV), "ABBV Research: Growth, Valuation and Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. AbbVie enters the weekend near its 52-week high after an adjusted earnings beat and strong growth from Skyrizi and Rinvoq. The company’s growth outlook and analyst support are balanced by a rich trailing P/E, modest consensus target upside, debt, and ongoing Humira erosion.

When was the ABBV research last updated?

The most recent ABBV report was published on November 14, 2026.

What do analysts expect for ABBV?

As of November 1, 2026, the analyst consensus on ABBV is Strong Buy (7 Strong Buy, 16 Buy, 5 Hold, 0 Sell, 1 Strong Sell). As of November 17, 2026, the analyst price target is $313.80 mean (range $275.00 to $340.00).

Is this ABBV research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring